Effects of GYKI 52466 on Early Vasospasm in Rats

Colak A., Soy O., Karaoglan A., Akdemir O., Kokturk S., Sagmanligil A., ...More

CENTRAL EUROPEAN NEUROSURGERY, vol.70, no.4, pp.187-194, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 4
  • Publication Date: 2009
  • Doi Number: 10.1055/s-0029-1202357
  • Journal Name: CENTRAL EUROPEAN NEUROSURGERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.187-194
  • Kocaeli University Affiliated: Yes

Abstract

Objective: The pathogenesis and treatment of cerebral vasospasm (CV) after subarachnoid hemorrhage (SAH) remains a matter of discussion. The authors investigated the efficacy of GYKI 52466, a 2,3-benzodiazepine that is a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) receptor antagonist, in a rat femoral artery vasospasm model.